Offers undergraduate and graduate medical programs. Provides medical residency preparatory courses. Now — the numbers.
This is an established company with proven profits.
Average growth of 20% a year over the last 4 years. Every year shown ended in profit.
The market pays 8.7× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
Against companies in its own sector, it looks cheaper than 93% of them.
Analysts' average target sits 21% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price looks reasonable next to what the company earns.
Clearly above the class average — a step short of the very top.
The price is looking for direction — no strong breakout, no collapse.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 38% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 20% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 20% a year on average.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Since the drop from its peak, buyer appetite hasn’t come back.
No clear buy-side message is coming from the executive floor.
On our five-subject report card, AFYA sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: AFYA is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.